Moclobemide: therapeutic use and clinical studies.

@article{Bonnet2003MoclobemideTU,
  title={Moclobemide: therapeutic use and clinical studies.},
  author={Udo Bonnet},
  journal={CNS drug reviews},
  year={2003},
  volume={9 1},
  pages={
          97-140
        }
}
  • U. Bonnet
  • Published 1 March 2003
  • Psychology, Medicine
  • CNS drug reviews
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a… Expand
Fatal serotonin toxicity caused by moclobemide and fluoxetine overdose.
TLDR
A lethal case of serotonin toxicity in a 36 year-old woman after she ingested multiple drugs, including moclobemide 4500 mg, fluoxetine 200 mg, propranolol 300 mg and several benzodiazepines is described. Expand
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
TLDR
The benzamide moclobemide's evolution, pharmacodynamic and pharmacokinetic properties are focused on, including the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. Expand
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
TLDR
VPA does not significantly affect PK or metabolism ofMCB, whereas CBZ time-dependently decreases MCB exposure, probably by inducing metabolism of MCB and its major plasma metabolite. Expand
Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
  • M. Thase
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2006
TLDR
The holy grail of this search for a better MAOI has been identification of a drug that did not require a special diet, has a tolerability and ease-of-use profile comparable to the selective serotonin reuptake inhibitors (SSRIs), and is as effective as tranylcypromine or phenelzine. Expand
Treatment of anxiety disorders with venlafaxine XR
  • M. Thase
  • Medicine
  • Expert review of neurotherapeutics
  • 2006
TLDR
The overall tolerability profile of venlafaxine XR is generally comparable to that of the SSRIs, although there is greater incidence of noradrenergically mediated side effects, and concerns about safety in overdose have also recently emerged. Expand
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of majorExpand
Acute and chronic treatment with moclobemide, a reversible MAO-inhibitor, potentiates the antielectroshock activity of conventional antiepileptic drugs in mice
TLDR
Acute and chronic therapy with moclobemide can increase the effectiveness of some antiepileptic drugs against the maximal electroshock test, and in mice, this effect was, at least partially, due to pharmacokinetic interactions. Expand
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
  • P. Gillman
  • Medicine, Chemistry
  • British journal of pharmacology
  • 2007
New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductionsExpand
Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice
TLDR
Investigating whether the selected CB receptor ligands can have an impact on the activity of bupropion and moclobemide revealed that particularly activation or inhibition of the CB1 receptor function may augment the antidepressant activity ofbupropion, whereas only inhibition of that function manages to increase activity of moclOBemide. Expand
Methylene blue and its analogues as antidepressant compounds
Methylene Blue (MB) is considered to have diverse medical applications and is a well-described treatment for methemoglobinemias and ifosfamide-induced encephalopathy. In recent years the focus hasExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 258 REFERENCES
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
TLDR
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
TLDR
When the tolerability of moclobemide, as judged by reported and observed adverse events, is compared to that of placebo, it appears that only nausea is reported significantly more frequently with moclOBemide than with placebo; in particular the incidence of anticholinergic side effects was low with mclobemides and was significantly higher with the TCAs. Expand
Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Efficacy of moclobemide in different patient groups: a meta-analysis of studies
TLDR
Moclobemide shows the same efficacy in depression as tricyclics: its effects are similar in unipolar and bipolar affective disorders, and in patients with major depressive episode superimposed on dysthymia (double depression). Expand
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
TLDR
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated. Expand
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
TLDR
It is suggested that therapeutic doses of moclobemide up to 300 mg daily can be given 24 hours after the last dose of treatment with either amitriptyline or clomipramine without major risks. Expand
Comparison of the Efficacy and Tolerability of Moclobemide and Maprotiline in Depressed Patients Treated by General Practitioners
TLDR
Moclobemide was the better‐tolerated drug, producing fewer side effects than maprotiline did, and appeared to have the same antidepressant and anxiolytic activity, but a stronger drive‐enhancing effect. Expand
Interaction studies with moclobemide
TLDR
Evidence is provided that amitriptyline can replace or be added to moclobemide without any sign of impaired tolerance, need for dose reduction or a therapy‐free interval, and replacement of the older, irreversible MAO inhibitors by a TCA is held to be dangerous and to require a therapy-free interval. Expand
An update of recent moclobemide interaction data
  • J. Dingemanse
  • Chemistry, Medicine
  • International clinical psychopharmacology
  • 1993
TLDR
In combination with therapeutic doses of either fluvoxamine or fluoxetine, moclobemide did not provide any indication of a serotoninergic syndrome, so that no wash-out period is needed when switching from a selective serotonin re-uptake inhibitor to moclOBemide or vice versa. Expand
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
TLDR
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
...
1
2
3
4
5
...